Global WholeHealth Partners focuses on using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 1⁄2 hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Throughout the years, Global WholeHealth have made their mark involving some of the deadliest diseases through their innovation of prompt and accurate test results. Established in 2013 & headquartered in San Clemente, CA the company currently has 56 products that are FDA approved. Global WholeHealth’s portfolio of products include OTC “Over-the-counter” and POC “point-of-care” testing methods.
Update on Global WholeHealth Partners Corp (OTC:GWHP) and Nunzia Pharmaceutical Inc. Agreement for Sales and Marketing; First Purchase Order is for $25,000 From Nunzia to Global
San Clemente, CA, May 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global WholeHealth Partners Corp (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains breakthrough on rising neurological disease and receives its first purchase order from Nunzia Pharmaceutical after the agreement was signed last month.
“This is the first of many Purchase Orders to Global as Nunzia plans on expansion,” stated Michael Mitsunaga, President of Nunzia Pharmaceutical Inc.
“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo. “Nunzia Pharmaceutical with nutraceutical for anxiety and stress based on their patented formulas and their pharmaceutical drug they are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests,” says Mr. Strongo. “With the new tests for Alzheimer’s, Parkinson’s and Dementia, Global is right in the path of success.”
The marketing and sales partnership with Nunzia Pharmaceutical with 8k filing dated 04/19/2021, gives Global the ability to sell the AstraZeneca Vaccine and the Johnson & Johnson vaccine and other products of Nunzia including their patented nutraceutical for stress and anxiety and soon FDA approved drug for ASD (Autistic Spectrum of Disorders), including Autism, ADD, ADHD, Fragile X, and PTSD. The Nunzia Nutraceutical aids in Nutritional deficiencies and therefore helps people.
Nutritional deficiencies. Not drinking enough liquids (dehydration); not getting enough thiamin (vitamin B-1), which is common in people with chronic alcoholism; and not getting enough vitamins B-6 and B-12 in your diet can cause dementia-like symptoms. Copper and vitamin E deficiencies also can cause dementia symptoms.
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, “The Company’s goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.”
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Phone for Sales: (949) 757-4152
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Original Source: https://www.globenewswire.com/news-release/2021/05/05/2223199/0/en/Update-on-Global-WholeHealth-Partners-Corp-OTC-GWHP-and-Nunzia-Pharmaceutical-Inc-Agreement-for-Sales-and-Marketing-First-Purchase-Order-is-for-25-000-From-Nunzia-to-Global.html
IMPORTANT NOTICE: The owner and contributors are NOT registered as Investment Advisers in any form at all. Readers should verify all claims and content from Stockify Media or affiliates. We encourage proper due diligence on any security mentioned. Likewise, note that by presenting a solicitation for a page on our site, or by pursuing any Stockify Media content you are unequivocally consenting to have read, comprehended, and consented to the entirety of the terms set out by this disclaimer. This disclaimer is provided because we are in the business of publishing advertisements and disseminating information on penny stocks. Therefore, certain communication disclosures must be made to viewers. The companies are commonly referred to as “penny stocks”. These “penny stock” securities are known to have high risk and speculative nature on the market. Stockify Media provides all buy, sell, or holding period disclosures on any profiled issuer. All our compensated disclosures can be viewed under the “Compensation Disclosure” heading at the bottom of this disclaimer. Stockify Media engages in posting and re-posting our sponsored clients public material. Stockify Media does not hold any position in the mentioned companies above. We have been compensated for this profile. Stockify Media, managers, and site contributors are not registered investment advisors in any form. Stockify Media is not responsible for maintaining the accuracy, integrity, and relevancy of third-party source data used in profiles. None of our information provided is a solicitation to buy or sell any security profiled by Stockify Media, LLC/Stockify Media. Our content is strictly for informational purposes only. This information is not intended and should not be used to make any investment decisions. We advise viewers to consult with a registered investment advisor prior to making any investment decisions. You are fully aware that you will lose your entire investment in any stocks mentioned. Our full disclaimer can be viewed here.